Comparative Pharmacology
Head-to-head clinical analysis: ERYGEL versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYGEL versus ZMAX.
ERYGEL vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation of peptidyl-tRNA.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Apply a thin layer to affected areas twice daily. Topical use only.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.0–2.5 hours) after topical application, too short to accumulate with daily use.
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Primarily hepatic metabolism; less than 10% excreted renally as unchanged drug. Biliary excretion is minimal.
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic